Phase II study of paclitaxel and cisplatin for advanced urothelial cancer

P. A. Burch, R. L. Richardson, S. S. Cha, D. J. Sargent, Henry Clement Pitot, Judith S Kaur, John K Camoriano

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer. Materials and Methods: A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles. Results: Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe. Conclusions: This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.

Original languageEnglish (US)
Pages (from-to)1538-1542
Number of pages5
JournalJournal of Urology
Volume164
Issue number5
StatePublished - 2000

Fingerprint

Neoplasms
Leukopenia
Anorexia
Paclitaxel
Thrombocytopenia
Nausea
Cisplatin
Outpatients
Therapeutics
TP protocol

Keywords

  • Cisplatin
  • Neoplasms
  • Paclitaxel
  • Urothelium

ASJC Scopus subject areas

  • Urology

Cite this

Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. / Burch, P. A.; Richardson, R. L.; Cha, S. S.; Sargent, D. J.; Pitot, Henry Clement; Kaur, Judith S; Camoriano, John K.

In: Journal of Urology, Vol. 164, No. 5, 2000, p. 1538-1542.

Research output: Contribution to journalArticle

Burch, PA, Richardson, RL, Cha, SS, Sargent, DJ, Pitot, HC, Kaur, JS & Camoriano, JK 2000, 'Phase II study of paclitaxel and cisplatin for advanced urothelial cancer', Journal of Urology, vol. 164, no. 5, pp. 1538-1542.
Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC, Kaur JS et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. Journal of Urology. 2000;164(5):1538-1542.
Burch, P. A. ; Richardson, R. L. ; Cha, S. S. ; Sargent, D. J. ; Pitot, Henry Clement ; Kaur, Judith S ; Camoriano, John K. / Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. In: Journal of Urology. 2000 ; Vol. 164, No. 5. pp. 1538-1542.
@article{1886050839e44c41add4d3397480d164,
title = "Phase II study of paclitaxel and cisplatin for advanced urothelial cancer",
abstract = "Purpose: We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer. Materials and Methods: A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles. Results: Of the patients 70{\%} experienced a major response to treatment, which was partial/regression in 38{\%} and complete in 32{\%}. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe. Conclusions: This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.",
keywords = "Cisplatin, Neoplasms, Paclitaxel, Urothelium",
author = "Burch, {P. A.} and Richardson, {R. L.} and Cha, {S. S.} and Sargent, {D. J.} and Pitot, {Henry Clement} and Kaur, {Judith S} and Camoriano, {John K}",
year = "2000",
language = "English (US)",
volume = "164",
pages = "1538--1542",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Phase II study of paclitaxel and cisplatin for advanced urothelial cancer

AU - Burch, P. A.

AU - Richardson, R. L.

AU - Cha, S. S.

AU - Sargent, D. J.

AU - Pitot, Henry Clement

AU - Kaur, Judith S

AU - Camoriano, John K

PY - 2000

Y1 - 2000

N2 - Purpose: We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer. Materials and Methods: A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles. Results: Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe. Conclusions: This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.

AB - Purpose: We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer. Materials and Methods: A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles. Results: Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe. Conclusions: This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.

KW - Cisplatin

KW - Neoplasms

KW - Paclitaxel

KW - Urothelium

UR - http://www.scopus.com/inward/record.url?scp=0033789641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033789641&partnerID=8YFLogxK

M3 - Article

C2 - 11025699

AN - SCOPUS:0033789641

VL - 164

SP - 1538

EP - 1542

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -